Global Combination Cancer Immunotherapy Market Opportunity to 2028 – Includes Abbvie, Amgen and Eli Lilly –

DUBLIN–(BUSINESS WIRE)–Added Global Combination Cancer Immunotherapy Market Opportunity and Clinical Trials Insight 2028 report Offer.

According to the report results, the global combined immunotherapy market is expected to surpass US$15 billion by 2028. This is mainly due to the increasing geriatric population and an increase in the prevalence of various types of cancer. This has a high medical need for the development of targeted therapies in their management.

Furthermore, increasing investments by pharmaceutical companies are driving the growth of the market due to the promising response of combinatorial immunotherapy.

In recent years, cancer immunotherapy has emerged as an attractive strategy to overcome the limitations of conventional therapies. The novel therapy aims to harness the immune system’s ability to recognize, attack and destroy cancer cells.

Cancer immunotherapy now encompasses multiple therapeutic agents, including monoclonal antibodies, immune checkpoint inhibitors, vaccines, antibody-drug conjugates, and others. All of these novel approaches have their own goals and mechanisms of action.

Although immunotherapies have shown significant improvement in clinical outcomes in cancer patients, they come with several limitations. Tumor heterogeneity and resistance development are the greatest challenges for current immunotherapeutic approaches.

This has prompted research studies to evaluate immunotherapy in combination with other cancer-directed approaches, including chemotherapy, radiation therapy, targeted drugs, and other immunotherapeutic approaches. Combination therapy aims to combine two or more drugs that have a synergistic mechanism of action in fighting the disease.

Compared to monotherapy, combination therapy aims to provide an enhanced and additive effect in targeting cancer cells. In addition, it also has the potential to overcome drug resistance and improve overall survival in cancer patients. The benefits associated with combination therapies have attracted interest from several pharma giants to invest in this segment.

Currently, several drugs such as Opdivo, Yervoy, Bevacizumab and others have received approval as combinatorial immunotherapy for the management of cancer cells to treat adult and pediatric patients 12 years and older with unresectable or metastatic melanoma. The novel combination has demonstrated manageable safety with no new or unexpected safety signals. The combination is marketed under the trade name Opdualag and is marketed by Bristol Myers Squibb.

In recent years, pharmaceutical companies have started to adopt a more collaborative way of working in order to remove the obstacles in drug development. Manufacturers of antibody-drug conjugates are increasingly collaborating or forming partnerships with other companies to share technology, resources and product knowledge and grow the business.

companies mentioned

  • Abbvie

  • age

  • Akeso Pharmaceutical

  • amgen

  • Arbutus Biopharma

  • Astrazeneca

  • Aum Life Sciences

  • own

  • Biontech

  • Bristol Myers Squibb

  • Candel Therapeutics

  • Eli Lilli

  • Elicio Therapeutics

  • destiny therapy

  • GlaxoSmithKline

  • harpoon therapy

  • immutep

  • imugen

  • intensity therapy

  • Janssen Pharma

  • note

  • Morphosys

  • Novartis

  • Novocure

  • Nykode Therapeutics

  • Ono Pharma

  • Oxford Biotherapeutics

  • Pfizer

  • Qurient

  • Regeneron

  • Roche

  • Sanofi

  • blessings

  • Shanghai Junshi Life Sciences

  • Takeda Pharma

Report Highlights:

  • Global and Regional Combination Cancer Immunotherapy Market Insight up to 2028

  • Combined Cancer Immunotherapy Market Opportunity: >$15B

  • Combination cancer immunotherapy market of 15 different cancer types

  • Insight into clinically and commercially approved cancer immunotherapy combinations

  • Patent, price and dosage analysis for approved combination preparations

  • Global and regional sales insights on approved combination drugs through 2028

  • Insight into 600 combination cancer immunotherapeutics in clinical trials

  • Insight into 45 commercially approved combination cancer immunotherapy drugs on the market

  • Clinical trials and patent insights by company, country, indication and phase

Main topics covered:

1. Combination Cancer Immunotherapy – New Era in Cancer Research

2. Need for combination cancer immunotherapy

3. Clinically and commercially approved combination cancer immunotherapy

4. Global Combination Cancer Immunotherapy Market Size and Trends Analysis

5. Global Combination Cancer Immunotherapy Market Size and Trends Analysis by Indication

6. Global Combination Cancer Immunotherapy Market Size and Trends Analysis by Regions

7. Approved Immune Checkpoint Inhibitor in Combination Cancer Immunotherapy – Clinical and Commercial Insights

8. Approved Antibody-Drug Conjugate in Combination Cancer Immunotherapy – Clinical and Commercial Insights

9. Approved monoclonal antibodies in combination cancer immunotherapy – clinical and commercial insights

10. Overview of clinical studies on combination cancer immunotherapy

11. Combination Cancer Immunotherapy Clinical Trials and Patent Insights by Company, Country, Indication and Phase

12. Clinical and patent insights into marketed combination cancer immunotherapy by company, country and indication

13. Combination Strategies to Improve the Efficacy of Immune Checkpoint Inhibitors

14. Combination of therapeutic antibodies in clinical oncology

15. Inclusion of cancer vaccines in combination therapy

16. Antibody drug conjugate in combination therapy

17. Combination therapy with Car T cell therapy

18. Oncolytic viral combination therapy

19. Competitive Landscape

For more information about this report, visit

Leave a Comment